Karagkounis Georgios, Cai Guoxiang, Johnson Pamela T, Pawlik Timothy M, Fishman Elliot K, Choti Michael A
Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, USA.
Ann Surg Oncol. 2015 Jul;22(7):2201-8. doi: 10.1245/s10434-014-4206-4. Epub 2015 Jan 13.
Incidental pulmonary lesions are frequently found during the preoperative evaluation of patients considered for resection of colorectal liver metastases (CRLM), and their presence can confound management decisions. This study investigates the role of clinical and radiologic factors, including response to preoperative systemic chemotherapy, in determining the malignant probability of these lesions.
Computed tomography (CT) scans of 33 patients with small (≤1 cm) lung lesions undergoing resection for CRLM after preoperative chemotherapy were reviewed. Radiological features were recorded from three sequential CT scans (baseline, postchemotherapy, and follow-up). Malignancy was diagnosed either by resection or serial imaging. Chemotherapy response comparing lung lesions and CRLM was categorized as: (1) concordant or (2) discordant. Chemotherapy response, imaging features, and other clinical factors were evaluated in multivariate analyses as predictors of malignancy.
Among the 86 indeterminate lung lesions identified, 23 % (20/86) were found to be metastases on follow-up. Lesions 6-10 mm were more likely to be metastases (odds ratio [OR] = 3.14, p = 0.045), as were lesions located in the lower lobes (OR = 4.50, p = 0.018). Concordant chemotherapy response was found in 13 of 86 (15 %) and was independently associated with metastatic disease (OR = 19.87, p < 0.001), with 11 of 13 (85 %) lesions determined to be metastases. In contrast, only 9 of 73 lesions (12 %) with discordant response were found to be metastases.
Lesion size, location, and chemotherapy response pattern were independent predictors of malignancy for patients with resectable CRLM and small indeterminate lung lesions. Utilization of preoperative chemotherapy can be a useful method of ruling out pulmonary metastases in these patients.
在考虑行结直肠癌肝转移(CRLM)切除术的患者术前评估过程中,常发现意外的肺部病变,其存在会使治疗决策变得复杂。本研究调查临床和放射学因素,包括术前全身化疗反应,在确定这些病变恶性概率中的作用。
回顾了33例术前化疗后因CRLM行肺小(≤1cm)病变切除术患者的计算机断层扫描(CT)图像。从连续三次CT扫描(基线、化疗后和随访)记录放射学特征。通过切除或系列成像诊断恶性肿瘤。将肺病变和CRLM的化疗反应分为:(1)一致或(2)不一致。在多变量分析中评估化疗反应、成像特征和其他临床因素作为恶性肿瘤的预测因素。
在86个不确定的肺部病变中,23%(20/86)在随访中被发现为转移瘤。6 - 10mm的病变更可能是转移瘤(优势比[OR]=3.14,p = 0.045),下叶的病变也是如此(OR = 4.50,p = 0.018)。86个病变中有13个(15%)化疗反应一致,且与转移性疾病独立相关(OR = 19.87,p < 0.001),其中13个病变中有11个(85%)被确定为转移瘤。相比之下,反应不一致的73个病变中只有9个(12%)被发现为转移瘤。
对于可切除的CRLM和小的不确定肺部病变患者,病变大小、位置和化疗反应模式是恶性肿瘤的独立预测因素。术前化疗的应用可能是排除这些患者肺转移的一种有用方法。